The lab association fears that the FDA's recent proposed framework would give the agency "virtually unfettered discretion" to regulate LDTs.

In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.

Efforts are underway to standardize pharmacogenetic testing, but experts say more needs to be done to encourage broader acceptance of these recommendations.

Companies said at AACC that as labs grow larger, they see growth in demand for integrated, modular systems that help customers manage complexity and costs.